Correction to Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth: Targeted co-delivery of the iron chelator deferoxamine and a HIF1α inhibitor impairs pancreatic tumor growth (ACS Nano (2019) 13:2 (2176−2189) DOI: 10.1021/acsnano.8b08823)

Jiayan Lang, Xiao Zhao, Xiuchao Wang, Ying Zhao, Yiye Li, Ruifang Zhao, Keman Cheng, Yao Li, Xuexiang Han, Xiaowei Zheng, Hao Qin, Marzieh Geranpayehvaghei, Jian Shi, Gregory J. Anderson, Jihui Hao, He Ren, Guangjun Nie

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations

Abstract

The authors regret that some incorrect images were inadvertently used when VEGF expression was shown in the TNP-DFO and TNP-DFO-YC1 groups of Figure 6E. This error occurred during the assembly of the figure. The correct images have now been incorporated. These corrections do not change the conclusions, the text of the article, or the figure legend. The authors apologize for any inconvenience caused to readers.

Original languageEnglish (US)
Pages (from-to)1211
Number of pages1
JournalACS Nano
Volume14
Issue number1
DOIs
StatePublished - Jan 28 2020

ASJC Scopus subject areas

  • Materials Science(all)
  • Engineering(all)
  • Physics and Astronomy(all)

Fingerprint

Dive into the research topics of 'Correction to Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth: Targeted co-delivery of the iron chelator deferoxamine and a HIF1α inhibitor impairs pancreatic tumor growth (ACS Nano (2019) 13:2 (2176−2189) DOI: 10.1021/acsnano.8b08823)'. Together they form a unique fingerprint.

Cite this